And for its part, GSK won't concede that Sirtris' small molecules don't bind the targets. In an e-mailed statement, Ad Rawcliffe, head of GSK's WorldWide Business Development group, says ...
In a deal that could potentially be worth up to US$820 million, GlaxoSmithKline (GSK) has gained the exclusive, worldwide development and commercialization rights to retigabine, a first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback